Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Evan David Seigerman is an analyst at BMO Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/09/2024
Buy Now | Get Alert | ||||||||
---|---|---|---|---|---|---|---|---|---|
07/09/2024 | MORF | Buy Now | Morphic Holding | $55.70 | 2.32% | $52 → $57 | Downgrade | Outperform → Market Perform | Get Alert |
06/25/2024 | NVO | Buy Now | Novo Nordisk | $140.30 | 16.18% | $163 → $163 | Maintains | Outperform | Get Alert |
06/07/2024 | GPCR | Buy Now | Structure Therapeutics | $39.59 | 152.56% | $83 → $100 | Maintains | Outperform | Get Alert |
05/03/2024 | AMGN | Buy Now | Amgen | $314.75 | 12.79% | $336 → $355 | Maintains | Outperform | Get Alert |
05/02/2024 | PFE | Buy Now | Pfizer | $27.68 | 30.06% | $33 → $36 | Reiterates | Outperform → Outperform | Get Alert |
04/29/2024 | ABBV | Buy Now | AbbVie | $168.07 | 7.1% | $195 → $180 | Maintains | Outperform | Get Alert |
04/12/2024 | NVO | Buy Now | Novo Nordisk | $140.30 | 16.18% | → $163 | Initiates | → Outperform | Get Alert |
02/05/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.06K | 2.5% | $1055 → $1082 | Maintains | Outperform | Get Alert |
02/05/2024 | ABBV | Buy Now | AbbVie | $168.07 | 16.02% | $187 → $195 | Maintains | Outperform | Get Alert |
12/19/2023 | AMGN | Buy Now | Amgen | $314.75 | 3.57% | $286 → $326 | Upgrade | Market Perform → Outperform | Get Alert |
10/27/2023 | MRK | Buy Now | Merck & Co | $125.97 | 4.79% | → $132 | Upgrade | Market Perform → Outperform | Get Alert |
10/16/2023 | PFE | Buy Now | Pfizer | $27.68 | 19.22% | $44 → $33 | Maintains | Outperform | Get Alert |
10/06/2023 | MRTX | Buy Now | Mirati Therapeutics | — | — | $31 → $72 | Maintains | Market Perform | Get Alert |
10/03/2023 | GPCR | Buy Now | Structure Therapeutics | $39.59 | 109.62% | $40 → $83 | Maintains | Outperform | Get Alert |
09/28/2023 | MORF | Buy Now | Morphic Holding | $55.70 | -6.65% | $106 → $52 | Maintains | Outperform | Get Alert |
08/21/2023 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.06K | -6.69% | $960 → $985 | Maintains | Outperform | Get Alert |
08/09/2023 | MRTX | Buy Now | Mirati Therapeutics | — | — | $40 → $31 | Maintains | Market Perform | Get Alert |
08/02/2023 | PFE | Buy Now | Pfizer | $27.68 | 58.96% | $45 → $44 | Maintains | Outperform | Get Alert |
05/25/2023 | MRTX | Buy Now | Mirati Therapeutics | — | — | $50 → $40 | Maintains | Market Perform | Get Alert |
05/15/2023 | CADL | Buy Now | Candel Therapeutics | $5.91 | -49.24% | $9 → $3 | Maintains | Outperform | Get Alert |
04/26/2023 | MORF | Buy Now | Morphic Holding | $55.70 | 90.29% | $83 → $106 | Maintains | Outperform | Get Alert |
03/24/2023 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.06K | -1.48% | $1025 → $1040 | Maintains | Outperform | Get Alert |
03/01/2023 | MRTX | Buy Now | Mirati Therapeutics | — | — | $59 → $50 | Maintains | Market Perform | Get Alert |
02/01/2023 | PFE | Buy Now | Pfizer | $27.68 | 91.47% | $55 → $53 | Maintains | Outperform | Get Alert |
02/01/2023 | AMGN | Buy Now | Amgen | $314.75 | -19.62% | $276 → $253 | Maintains | Market Perform | Get Alert |
12/12/2022 | REPL | Buy Now | Replimune Group | $8.88 | 688.29% | $40 → $70 | Maintains | Outperform | Get Alert |
09/06/2022 | LLY | Buy Now | Eli Lilly | $932.95 | -57.55% | $369 → $396 | Maintains | Outperform | Get Alert |